Results 141 to 150 of about 928,578 (204)

Recruitment of Aβ into α‑Synuclein Condensates Catalyzes Primary Nucleation of α‑Synuclein Aggregation

ACS Central Science
Owen M. Morris, Alexander Röntgen, Zenon Toprakcioglu, Mariana Cali, Samuel Dada, Michele Vendruscolo   +5 more
doaj   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider, Divyani Garg, Vassilena Iankova, Thomas Klopstock   +3 more
wiley   +1 more source

Disease‐Duration–Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI‐Based Study

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data‐driven diffuse malignant (DM), intermediate (IM), and mild‐motor predominant (MMP) subtyping model has prognostic value but lacks disease duration–specific thresholds for prospective use in disease ...
Ahmed Negida, Nitai Mukhopadhyay, Brian D. Berman, Seyed‐Mohammad Fereshtehnejad, Matthew J. Barrett   +4 more
wiley   +1 more source

Machine Learning Prediction of Hoehn and Yahr Scores at 5‐Years Post‐123I‐Ioflupane SPECT Imaging in a Real‐World Parkinson's Disease Dataset

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) progression is highly heterogeneous, complicating clinical management and prognostication. While machine learning models have been developed using research datasets such as Parkinson's Precision Medicine Initiative (PPMI) and Parkinson's Disease Biomarkers Program (PDBP), their clinical translatability is ...
Xuehua Ye, Mette Niemann Johansen, Balazs Laczi, Mads Peter Horndrup, Michael Zaucha Sørensen, Rasmus Vestergård Madsen, Jan Wolber, Markus Lonsdale, Annemette Lokkegaard, Renee Miller   +9 more
wiley   +1 more source

JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link?

Movement Disorders Clinical Practice, EarlyView.
Abstract Background JAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well‐recognized neurological occurrence in this context ...
Elena Ardila Jurado, Koustubh Bavdhankar, Divyani Garg, Francesca Magrinelli, Huw R. Morris, Kailash P. Bhatia   +5 more
wiley   +1 more source

PREDICT‐PD: A Two‐Stage Approach to Early Identification of Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sasivimol Virameteekul, Sheena Waters, Brook Huxford, Ashvin Kuri, Manuela Tan, Laura Pérez‐Carbonell, Eduardo de Pablo‐Fernández, Anette Schrag, Alastair J. Noyce, Cristina Simonet   +9 more
wiley   +1 more source

Toxicity Differences Between Microplastics and Nanoplastics in Organs: From Molecular Mechanisms to Potential Therapeutic Strategies

Med Research, EarlyView.
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng, Junjie Chen, Rui Fu, Jiawei Zhang, Jianguang Jia, Wei Wang, Zheng Zhang, Peng Zhang, Haosong Chen, Huake Cao, Gang Li, Weiwei Sheng, Ting Li, Bo Chen, Guodong Cao   +14 more
wiley   +1 more source

Recent Advances in Exosome‐Based Nanodelivery Systems for Traumatic Brain Injury Treatment

Med Research, EarlyView.
An overview of functional modification, therapeutic effects, molecular composition, and delivery strategies for exosomes. ABSTRACT Traumatic brain injury (TBI) is a highly heterogeneous neurological condition with extremely high rates of mortality and disability.
Jue Zhu, Weiquan Liao, Ziqi Lian, Mengdan Zhang, Chenxing Wang, Xingjia Zhu, Lin Zhang, Jian Chen, Zhichao Lu, Peipei Gong   +9 more
wiley   +1 more source

The Ecology of Care in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Joaquin A. Vizcarra
wiley   +1 more source